Esomeprazole for gastroesephageal reflux disease:a systematic review

Abstract

Abstract: AIM: To evaluate the efficacy of esomeprazole in the treatment of gastroesephageal reflux disease(GERD) when compared to the other PPI.METHODS: We were searching RCT researchers contacted.The quality evaluation of studies and data analysis were conducted by the methods of the Cochrane Collaboration.RESULTS: Fourteen RCTs met the inclusion criteria.In patients with NERD symptom relief rate esomeprazole had significant effect when compared with pantoprazole.In patients with EE symptom relief rate esomeprazole had significant effect comparing with the other PPI.CONCLUSION: Esomeprazole was better than pantoprazole in patients with NERD symptom relief rate.In patients with EE symptom relief rate esomeprazole was better than the other PPI.

Key words: esomeprazole, gastroesephageal reflux disease, systematic review, Meta-analysis

CLC Number:

R969

ZHONG Li-chun, JIA Hong, LI Chang-ping, ZHOU Yi-jun. Esomeprazole for gastroesephageal reflux disease:a systematic review[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(10): 1154-1159.

References

1 陶嘉言永.胃食管反流病[ A].见:萧树东, 主编.江绍基胃肠病学[M].第1 版.上海:上海科学技术出版社, 2001:346-9
2 中华消化内镜学会.反流性食管病(炎) 诊断及治疗方案(试行)[J].中华消化内镜杂志, 1999;16:3266
3 傅宝玉, 姜敏.胃食管反流病的治疗[J].实用医院临床杂志, 2004;1:6
4 吴本俨.胃食管反流病药物治疗的现代观点[J].中华老年多器官疾病杂志, 2004;3:167-70
5 钟捷.埃索美拉唑与奥美拉唑对胃食管反流病24 小时胃内pH 效果比较[J].中华消化杂志, 2003;23:491-2
6 Armstrong D, Bennett JR, Blum AL.The endoscopic assessment of esophagitis:A progress report on observer agreement[J].Gastroenterology, 1996;111:85-92
7 Egger M, Smith GD, Altman DG.Sy stematic reviews in heath care[M].Second edition.London:Tavistock Square, 2001:73
8 Jadad AR, Moore A, Carrol D, Jenkinson C, Reynolds JM,Gavaghan DJ.Assessing the quality of reports of randomized clinical trials:Is blinding necessary[J].Control Clin Trials,1996;17:1-12
9 The Cochrane Collaboration.Cochrane Reviewer's Handbook 4.2.2[M] , 2000
10 钟捷.埃索美拉唑与兰索美拉唑治疗糜烂性食管炎疗效比较[J].中华消化杂志, 2003;23:366-7
11 Lauritsenl K, Deviere J, Bigard MA.Esomeprazole 20 mg and lansoprazole 15mg in maintaining healed reflux oesophagitis:Metropole study results[J].Aliment Pharmacol Ther, 2003;17:333-41
12 Gillessen A,Winfried B, Irvin M.40 mg pantoprazole and 40 mg esomeprazole are equivalent in the healing of esophageal lesions and relief from gastroesophageal reflux disease-related symptoms[J].J Clin Gastroenterol, 2004;38:332-40
13 Scholten T,Gatz G, Hole U.Once-daily pantoprazole 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD-related symptoms[J].Aliment Pharmacol Ther, 2003;18:587-94
14 Labenz J, Armstrong D, Lauritsen K.A randomized comparative study of esomeprazole 40mg versus pantoprazole 40mg for healing erosive oesophagitis:the EXPO study[J].Aliment Pharmacol Ther, 2005;21:739-46
15 Kahrilas PJ, Falk GW, Johnson DA, Schmitt C, Collins DW,Whipple J, et al.Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients:a randomized controlled trial[J].Aliment Pharmacol Ther, 2000;14:1249-58
16 Joel ER, Peter JK, John JohansonMSc, Paul Maton, Jeffrey RB,Clara Hwang MS, et al.Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis:a randomized controlled trial[J].Am J Gastroenterol,2001;96:656-65
17 Kao AW, Sheu BS, Sheu MJ, Chang YM, Huang SF, Chuang CH, et al.On-demand therapy for Los Angeles grade A and B reflux esophagitis:esomeprazole versus omeprazole[J].J Formos Med Assoc, 2003;102:607-12
18 宋振河, 宋震亚, 蔡建庭, 杜勤, 钱可大, 唐训球.埃索美拉唑治疗反流性食管炎疗效观察[J].浙江医学, 2004;26:859-60
19 郑海泉.埃索美拉唑合并多潘里酮治疗反流性食管炎118 例临床观察[J].中国社区医师, 2005;21:222-3
20 陈跃华, 徐为红, 黄伟.埃索美拉唑与奥美拉唑治疗反流性食管炎的疗效比较[J].浙江临床医学, 2004;6:1064-5
21 蔡荣蓝, 颜殷红.埃索美拉唑治疗胃食管反流病31 例疗效观察[J].福建医药杂志, 2004;26:176-7
22 王建刚, 龙辉, 陶萍.埃索美拉唑治疗胃食管反流病疗效观察[J].中国医院药学杂志, 2004;24:494-5

[1]	MA Guangli, ZHANG Jing. Application of quantitative pharmacology in vaccine research and de-velopment: overview and prospect [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 315-322.
[2]	YE Hongbo, SONG Yangyang, XUE Ling, RUI Jianzhong. Meropenem population pharmacokinetic model for the Chinese elderly established by model-based META analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 984-990.
[3]	YU Zhaolei, BAI Jianling, YU Hao, ZHAO Yang. Development of tools for clinical trial information retrieval and Meta-analysis based on R-Shiny: Taking non-small cell lung cancer as an example [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 984-991.
[4]	CHEN Wenjun, RUAN Zourong, XIANG Xiaoqiang. Development and application progress of physiologically based pharmacokinetic modeling and its combined use with other modeling methods [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(3): 299-305.
[5]	LI Lujin, DING Junjie, LIU Dongyang, WANG Xipei, DENG Chenhui, JI Shangmin, CHEN Wenjun, MA Guangli, WANG Kun, SHENG Yucheng, XU Ling, PEI Qi, CHEN Yuancheng, CHEN Rui, SHI Jun, LI Gailing, WANG Yaning, WANG Yuzhu, XIE Haitang, ZHOU Tianyan, FANG Yi, ZHANG Jing, JIAO Zheng, HU Bei, ZHENG Qingshan. General considerations of model-based meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(11): 1250-1267.
[6]	SHAO Yaojun, ZHENG Tong,WANG Yanqiu,LIU Ling,YAO Yingshui. Nimodipine combined with flunarizine for preventing and treating migraine: A Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(6): 646-652.
[7]	WEI Liuping, WU Qing, YIN Nange, YANG Bin, MAO Jinxiao. Effect and safety of lactoferrin for prevention of late-onset sepsis in premature neonates: a systematic review [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(6): 653-660.
[8]	WANG Weiyu, YU Hao. Effects of gray drugs in patients with coronary heart disease: A network Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(3): 301-307.
[9]	WU Jiaqi, YANG Qiaowen, CHEN Xiumin, HUANG Runyue, HUANG Qingchun, ZHAO Yue, WU Xiaodong. Efficacy and safety of iguratimod combined with methotrexate in rheumatoid arthritis: A systematic review and Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(10): 1132-1140.
[10]	ZHANG Chunyan, FAN Xiaodong, QIN Yuan, KONG Wenqiang, ZHOU Chunyang, DU Biao. Markov model to assess long-term effects of teneligliptin in treatment of type 2 diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(1): 65-72.
[11]	ZHANG Xiaoyu, FANG Zhengmei, YAO Yingshui. Association of leptin and leptin receptor gene polymorphisms with hypertension: a Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(8): 910-916.
[12]	LI Yun, LI Bingsheng, ZHANG Weifang, LI Yixiu, LI Chun, PENG Juan, LAI Xin, ZHU Jing, XU Ruilai, XIONG Aizhen. Association study of miR-146a G>C polymorphisms with susceptibility of hepatocellular carcinoma in the Chinese population: a Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(7): 779-786.
[13]	RONG Guoyi, WANG Shumei, TANG Mo. Efficacy of reducing phlegm with traditional Chinese medicine on non-small cell lung cancer: a Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(7): 787-794.
[14]	FANG Xiaobi, ZHOU Qinshuang, LIAO Zhisu. Effect of intralesional diprospan injection combined with esomeprazole acid-suppressive on laryngeal contact granuloma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(6): 680-683.
[15]	WU Changjuan, TANG Tiansheng. Efficacy of Zhenyuan capsule as adjuvant therapy for chronic heart failure: a Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(3): 299-304.